Lupin gets FDA approval for Vigabatrin for Oral Solution USP, 500 mg
Lupin Limited said that it has secured approval for Vigabatrin for Oral Solution USP, 500 mg, an anti-epileptic drug, from the US Food and Drug ... Read More
Lundbeck to acquire Prexton Therapeutics in $1.1bn deal to expand Parkinson’s Disease treatment portfolio
Lundbeck, a leading Danish pharmaceutical company, has announced its acquisition of Prexton Therapeutics, a Swiss firm specializing in the development of drugs for Parkinson's disease, ... Read More